Travel-related hepatitis E: a two-decade GeoSentinel analysis.


Journal

Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456

Informations de publication

Date de publication:
09 Nov 2020
Historique:
received: 29 06 2020
revised: 27 07 2020
accepted: 06 08 2020
pubmed: 14 8 2020
medline: 29 7 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

Hepatitis E virus (HEV) is widely distributed worldwide and is endemic in developing countries. Travel-related HEV infection has been reported at national levels, but global data are missing. Moreover, the global availability of HEV diagnostic testing has not been explored so far. The aim of this study is to describe the epidemiology of HEV infections in returning travellers and availability of HEV diagnostic testing in the GeoSentinel surveillance network. This was a multicentre retrospective cross-sectional study. All confirmed and probable HEV travel-related infections reported in the GeoSentinel Network between 1999 and 2018 were evaluated. GeoSentinel sites were asked to complete a survey in 2018 to assess the availability and accessibility of HEV diagnostic procedures (i.e. serology and molecular tests) throughout the study period. Overall, 165 travel-related HEV infections were reported, mainly since 2010 (60%) and in tourists (50%). Travellers were exposed to hepatitis E in 27 countries; most travellers (62%) were exposed to HEV in South Asia. One patient was pregnant at the time of HEV infection and 14 had a concomitant gastrointestinal infection. No deaths were reported. In the 51% of patients with information available, there was no pre-travel consultation. Among 44 GeoSentinel sites that responded to the survey, 73% have access to HEV serology at a local level, while 55% could perform (at a local or central level) molecular diagnostics. Reported access to HEV diagnostic testing is suboptimal among sites that responded to the survey; this could negatively affect diagnosing HEV. Pre-travel consultations before travel to South Asia and other low-income and high-prevalence areas with a focus on food and water precautions could be helpful in preventing hepatitis E infection. Improved HEV diagnostic capacity should be implemented to prevent and correctly diagnose travel-related HEV infection.

Sections du résumé

BACKGROUND BACKGROUND
Hepatitis E virus (HEV) is widely distributed worldwide and is endemic in developing countries. Travel-related HEV infection has been reported at national levels, but global data are missing. Moreover, the global availability of HEV diagnostic testing has not been explored so far. The aim of this study is to describe the epidemiology of HEV infections in returning travellers and availability of HEV diagnostic testing in the GeoSentinel surveillance network.
METHODS METHODS
This was a multicentre retrospective cross-sectional study. All confirmed and probable HEV travel-related infections reported in the GeoSentinel Network between 1999 and 2018 were evaluated. GeoSentinel sites were asked to complete a survey in 2018 to assess the availability and accessibility of HEV diagnostic procedures (i.e. serology and molecular tests) throughout the study period.
RESULTS RESULTS
Overall, 165 travel-related HEV infections were reported, mainly since 2010 (60%) and in tourists (50%). Travellers were exposed to hepatitis E in 27 countries; most travellers (62%) were exposed to HEV in South Asia. One patient was pregnant at the time of HEV infection and 14 had a concomitant gastrointestinal infection. No deaths were reported. In the 51% of patients with information available, there was no pre-travel consultation. Among 44 GeoSentinel sites that responded to the survey, 73% have access to HEV serology at a local level, while 55% could perform (at a local or central level) molecular diagnostics.
CONCLUSION CONCLUSIONS
Reported access to HEV diagnostic testing is suboptimal among sites that responded to the survey; this could negatively affect diagnosing HEV. Pre-travel consultations before travel to South Asia and other low-income and high-prevalence areas with a focus on food and water precautions could be helpful in preventing hepatitis E infection. Improved HEV diagnostic capacity should be implemented to prevent and correctly diagnose travel-related HEV infection.

Identifiants

pubmed: 32789467
pii: 5891692
doi: 10.1093/jtm/taaa132
pmc: PMC9494553
mid: NIHMS1835348
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCEZID CDC HHS
ID : U50 CK000189
Pays : United States

Informations de copyright

© International Society of Travel Medicine 2020. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Références

PLoS Negl Trop Dis. 2019 Jul 25;13(7):e0007453
pubmed: 31344038
Nat Rev Dis Primers. 2017 Nov 16;3:17086
pubmed: 29154369
J Hepatol. 2018 Jun;68(6):1256-1271
pubmed: 29609832
J Clin Virol. 2019 Nov;120:20-26
pubmed: 31536936
Epidemiol Infect. 2011 Aug;139(8):1145-50
pubmed: 20854712
Emerg Infect Dis. 2018 Jun;24(6):1055-1060
pubmed: 29774856
J Travel Med. 2019 Sep 2;26(6):
pubmed: 31407776
MMWR Surveill Summ. 2013 Jul 19;62:1-23
pubmed: 23863769
J Virol. 2017 Apr 13;91(9):
pubmed: 28202767
J Travel Med. 2016 Apr 11;23(4):
pubmed: 27069000
J Med Microbiol. 2018 Apr;67(4):466-480
pubmed: 29485390
J Infect Dis. 1997 Sep;176(3):763-6
pubmed: 9291328
Adv Exp Med Biol. 2016;948:89-112
pubmed: 27738981
Intervirology. 1983;20(1):23-31
pubmed: 6409836
J Travel Med. 2018 Jan 1;25(1):
pubmed: 30508133
Water Res. 2019 Mar 15;151:144-157
pubmed: 30594083
J Viral Hepat. 2019 Nov;26(11):1240-1248
pubmed: 31095813
J Travel Med. 2013 Jul-Aug;20(4):232-6
pubmed: 23809073
Med Microbiol Immunol. 2019 Dec;208(6):715-725
pubmed: 30903372
PLoS One. 2018 Jan 25;13(1):e0191798
pubmed: 29370254
Euro Surveill. 2019 Mar;24(10):
pubmed: 30862338
Am J Epidemiol. 2010 Oct 15;172(8):952-61
pubmed: 20801864
J Med Virol. 2004 Nov;74(3):419-24
pubmed: 15368508
Lancet. 2010 Sep 11;376(9744):895-902
pubmed: 20728932
Lancet. 2012 Jun 30;379(9835):2477-2488
pubmed: 22549046

Auteurs

Laura Ambra P Nicolini (LAP)

Infectious Diseases, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.

Rhett J Stoney (RJ)

Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Andrea Della Vecchia (A)

Department of Health Sciences, University of Genova, Genova, Italy.
Internal Medicine Unit, Hôpitaux Iris Sud, Bruxelles, Belgium.

Martin Grobusch (M)

Tropical Medicine at the Amsterdam Medical Center, Amsterdam, The Netherlands.

Philippe Gautret (P)

IHU Méditerranée Infection, Marseille, France.

Kristina M Angelo (KM)

Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Perry J J van Genderen (PJJ)

Erasmus MC University Hospital, Rotterdam, The Netherlands.

Emmanuel Bottieau (E)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, The Netherlands.

Karin Leder (K)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia.

Hilmir Asgeirsson (H)

Clinic of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Daniel T Leung (DT)

International Travel Clinic, University of Utah Hospital and Clinics, Salt Lake City, UT, USA.

Bradley Connor (B)

The New York Center for Travel and Tropical Medicine, New York City, USA.

Prativa Pandey (P)

The CIWEC Clinic Travel Medicine Center, Lainchaur, KTM, Nepal.

Federica Toscanini (F)

Infectious Diseases, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.

Federico Gobbi (F)

Department of Infectious-Tropical Diseases and Microbiology (DITM), IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.

Francesco Castelli (F)

Clinica di Malattie Infettive e Tropicali, University of Brescia, Brescia, Italy.

Matteo Bassetti (M)

Infectious Diseases, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.
Department of Health Sciences, University of Genova, Genova, Italy.

Davidson H Hamer (DH)

Department of Global Health, Boston University School of Public Health, Boston, USA.
Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH